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Obese patients are more likely to suffer from severe asthma symptoms and less likely to be able 
to control them. In obese patients, there is evidence that shows decreased efficacy of inhaled 
corticosteroids and beta-2 adrenergic agonists, the core treatment options for achieving and 
maintaining asthma control. This may be due to mechanical reasons like decreased ventilation 
and medication delivery, but there are many more pathologies of obesity that interact with 
pathways of both asthma pathology and asthma control. This review explores the epidemiological 
significance of obesity, many physiological changes in patients with obesity, the physiological 
interactions of asthma and obesity in patients with both issues, and the therapeutic impacts of 
these interactions with asthma to find appropriate areas where new research is needed. More 
research to understand the mechanism of decreased inhaled corticosteroid and beta-2 adrenergic 
agonist efficacy is necessary to improve treatment efficacy and decrease morbidity and mortality 
in this population of patients with asthma.  
 
The epidemiological significance of obesity 
 
 Obesity is a complex metabolic disorder that is defined as having a BMI >30 in adults or 
>95th percentile in children when accounting for age and sex.cdc Although BMI has been a 
convenient measure for stratifying risk groups within obesity, some refinements have been 
suggested. While, BMI is calculated by taking a person’s weight relative to their height (kg/m2), it 
fails to differentiate fat from muscle or account for anatomical fat distribution. Increases in 
subcutaneous fat, below the skin and in the extremities is less associated with negative health 
impacts than increases in visceral fat, located between abdominal organs.Harvard Using waist to hip 
ratios, abdominal circumference, and BMI will better approximate an  individual's potential 
negative health impacts due to body fat.Harvard 
In United States, obesity prevalence (in adults) has gradually increased from 33.7% (in 
2007-08) to 39.6% (in 2015-16)Hales The 2017-2018 National Health and Nutrition Examination 
Survey (NHANES) estimated adult obesity prevalence in the US to be  42.4% with no significant 
difference by sex or age group.cdc Obesity-linked morbidity and mortality increase with its 
prevalence, however, not every demographic section is affected equally by the disorder. In 2017-
2018 NHANES survey, Non-Hispanic black adults had the highest obesity prevalence at 
49.6%.CDC Hispanic adults and non-Hispanic white adults prevalence are estimated at 44.8% and 
42.2% respectively, while non-Hispanic Asians showed a much lower prevalence of 17.4%.CDC 
Possible explanations for this disparity include the social and economic reasons such as limited 
healthy nutrition options, accommodations for physical exercise, and healthcare 
accessiblity.Petersen Obesity in children is also growing more common with increasing morbidity. 
Prevalence in patients aged 2-19 has increased from 13.9% in data collected from 1999 and 2000 
to 18.5% for data from 2015 and 2016 representing a 33% increase over 16 years.Sanyaolu 
Obesity is a complex metabolic disorder with the capacity to affect all physiological 
systems and is commonly identified as a major contributor to cardiovascular diseases.Pi-Sunyer 
Obesity is also a major risk factor and modifier for other diseases. Complications of obesity include 
 
diabetes, hypertension, heart disease, stroke, sleep apnea, fatty liver disease, gallstones, 
osteoarthritis, mental illness and some cancers.CDC Further, obesity can negatively impact mental 
health and quality of life through decreased mobility leading to a higher risk of social isolation and 
depression.mayoclinic  Obesity in children also negatively impacts cardiovascular and mental health 
leading to similar increases in morbidity and mortality.Sanyaolu Thus, it is essential to understand 
the severity of obesity to enable mitigation of health risks it poses.  
 
Obesity and multisystem physiological disruption 
 Obesity can disrupt distinct physiological processes and result in hypertension, 
hyperglycemia, hypertriglyceridemia, decreased HDL cholesterol, and increased visceral fat.NIDDK 
Increased fat deposition near and in organs can negatively affect organ functions. Excess hepatic 
fat deposition leads to dysfunction and increased amounts of damaging reactive oxygen species 
that can harm other areas like skeletal muscle and nervous tissue.Gonzalez Increased perirenal fat 
may result in hypertension.Hall Increased peripancreatic fat necrosis may be the explanation for 
the positive association between obesity and severe acute pancreatitis.Kim Lung function can be 
affected by fat deposition in several ways.  
Many studies have emphasized a link between obesity and decreased lung 
function.Forno,Lawson In obese adults all lung volumes including FEV1, FVC, TLC, and RV are 
decreased.Forno This is consistent with a restrictive lung pathology where the work of breathing is 
increased and ventilation is decreased. Further, both obese adults and children show a decreased 
FEV1/FVC ratio with the reduction in children being >2 times that of adults independent of asthma 
status.Forno This is consistent with an obstructive lung pathology.  
Increase in truncal fat and associated inflammatory disposition are the two major factors 
that contribute to compromised lung function in obesity, This may be due to both physical 
restriction of movement due to fat deposition on the chest wall and inflammatory pathways 
decreasing airway lumen diameter. Extra adipose tissue poses a mechanical obstruction by 
 
increasing intrathoracic pressure by compressing the chest wall downward restricting lung filling. 
Lawson Abdominal adipose tissue opposes the diaphragm contraction leading to a further increase 
in intrathoracic pressure.Lawson  Further, the obstructive lung pathology found by Forno et al. in 
obese patients may worsen lung function even more.  
Obesity as a modifier of asthma 
The increasing prevalence of obesity and its specific effects on respiratory health have 
raised questions on the ability of obesity to influence the pathophysiology of asthma. Obesity is a 
major risk factor for asthma.Peters Almost 60% of adults with severe asthma are obese.Schatz  A 
2010 CDC survey showed that obesity rate among adults with current asthma was 38.8% while 
the prevalence among adults without current asthma was just 26.8%.cdcasthma Obese patients are 
also more likely to have more severe symptoms and more difficulty controlling symptoms. Obese 
patients with asthma are hospitalized up to 250% more for an asthma exacerbation due to 
uncontrollable symptoms.Rance Mechanisms for more severe asthma in obese patients include 
restriction of ventilation, decreased physical activity, increased inflammation, and activation of 
free fatty acid receptors.Mohanan, Lange  Most asthmatics with severe symptoms have atopic asthma 
which has a known pathophysiology driven by TH2 inflammation.Peters Some adipokines, 
especially leptin, have been shown to affect airway remodeling. Sildelva  Increased leptin has a 
demonstrated association with increased asthma severity and prevalence in prepubescent boys 
and postpubescent women, but this association is not as strong in other populations.Assad  Leptin 
also has positive associations with prevalence and severity of COPD, another obstructive lung 
pathology.Assad Though the mechanism is not yet clear it seems likely leptin worsens asthma’s 
obstructive pathology. Adiponectin has shown a more complex relationship with asthma and lung 
function. It has been shown to be positively associated with lung function in healthy patients while 
having a negative association in COPD patients.Assad This suggests that adiponectin can have 
both proinflammatory and antiinflammatory effects that may be subject to certain physiologic 
conditions.Assad These inflammatory and metabolic changes have complex and far reaching 
 
ramifications. The ventilation restriction and lack of physical activity can be largely addressed with 
weight loss and lifestyle modifications, but the inflammation pathway changes and airway 
remodeling in obese asthmatics may be effective pharmacologic targets for controlling symptoms. 
Obesity also varies in its effects on asthmatics based on the timing of asthma development and 
other epidemiologic factors. Early onset obese asthmatics (less than 12 yrs at asthma diagnosis) 
had more airway obstruction and bronchial hyperresponsiveness. Holguin This suggests that age 
related differences also play into differences in obese asthma severity and that slowing weight 
gain in childhood and adolescence is important.    Similar racial disparities exist in asthma and 
obesity. Black children are more than twice as likely to have asthma and are 4 times more likely 
to be hospitalized for asthma symptoms. akinbami,minorityhealth Mechanisms for this link may include 
socioeconomic and environmental reasons such as exposure to allergens or tobacco smoke.Barnes 
This is likely relevant to the increased atopic asthma prevalence in inner cities.Kakumanu There is 
also a lack of studies on asthma associated genetics that include minorities in their studies.Barnes, 
White Studies inclusive of these populations could improve the effectiveness of current 
management regimens and strengthen understanding of etiological differences.    
Another compounding issue is that obesity has also been shown to decrease the rate of 
nasomucociliary clearance.IJMRHS In atopic asthmatics this decrease in mucous clearance would 
make it more difficult to clear their triggering antigens and other pathogens. Atopic asthmatics 
make up a significant proportion of inner-city asthmatics where obesity prevalence and associated 
morbidity are high.Kakumanu This population has a large overlap with the ethnic minority populations 
that are more prone to obesity and asthma intensifying the severity of asthma in these patients 
even further.  
 
Impact of obesity on therapeutic management of asthma  
Asthma treatment is individualized based on clinical correlates and control of symptoms 
is often achievable using bronchodilators and inhaled/oral corticosteroids. The simplified 
 
American Thoracic Society table below shows the medications available and an often used step 
up treatment model.  
 
 
Table 1: American Thoracic Society Recommendations 
Inhaled corticosteroids are the preferred treatment for any asthma that includes persistent 
symptoms.Liang Montelukast can be used if steroids are not the best patient choice due to cost, 
adverse effects, or issues with inhaled medication.ATS  Beta-2 adrenergic receptor agonists (2 
agonists) are the treatment of choice for managing acute symptoms in patients with asthma.Svedmyr 
The advent of monoclonal antibody therapies (or biologics) has gained significant traction in the 
recent years. Omalizumab is a monoclonal antibody that binds to IgE preventing it from 
 
associating with basophils and mast cells preventing their response to allergens.Beck Thus it is 
primarily used to treat symptoms associated with atopic IgE mediated asthma. Among the factors 
that could influence effectiveness of the primary asthma controller, Inhaled Corticosteroids (ICS), 
and the primary treatment, 2 agonists, may be the adipokines and chronic inflammation status 
associated with obesity. The obstructive and restrictive lung pathologies also decrease the 
likelihood that these inhaled medications reach their target lung tissue by decreasing lung filling 
and decreasing the lumen diameter these inhaled medications can flow through.  
There are no specific pharmaceutical recommendations to treat asthma symptoms in 
obese asthmatics. The NIH guidelines mentions obesity as a possible comorbidity and that weight 
reduction may improve asthma control and many studies support this claim.Juel However, multiple 
studies have demonstrated that obese asthmatics receive suboptimal control of their symptoms. 
This could be due to the difficulty in achieving and maintaining weight control as well as the 
differences in responsiveness to first line medications. A study of asthma control in obese Black 
and Hispanic children and adolescents in the US showed decreased responsiveness to 2 
agonists  based on reports of increased wheezing, exacerbations of nighttime asthma symptoms, 
and increased use of other pharmacologic interventions like montelukast .Mcgarry Further studies 
showed therapeutic responsiveness to ICS in obese asthmatic children is diminished and that 
nonobese children were hospitalized 44% less frequently for asthma exacerbations.Forno This lack 
of symptom control was also demonstrated in adults with persistent asthma. Obese adult patients 
with asthma are more likely to be prescribed greater amounts of 2 agonists but are still 1.40 
times more likely to have an emergency department visit or hospitalization.Schatz2 This underscores 
an excessive reliance by physicians and their obese patients on 2 agonists, but an inability for 
obese asthmatics to control severe symptoms with this class of drugs.  
In summary, obese patients are associated with poorer asthma control and have 
demonstrated lack of response to first line rescue treatments and daily controllers. This is a clarion 
 
call for the development of strategies and therapeutic considerations that targets asthma 
management specifically in obese patients. Weight loss is an effective way to improve health 
outcomes in obese asthamtics and 5-10% of loss in body weight in adult obese asthmatics 
achieved through exercise and diet control effectively improves asthma control.Scott This study 
also showed that reduced circulation of saturated fat had a direct correlation with decreased 
neutrophils in airways, and increased exercise associated with decreased airway eosinophilia.Scott 
Although, weight loss and exercise are essential behavioral approaches in managing asthma in 
obese patients, effective control can be difficult to achieve and sustain weight loss especially 
when asthma symptoms make exercise more difficult. Weight loss is also a long-term solution 
however, it does not address the decreased responsiveness to asthma medications. Addressing 
pharmacodynamic differences in these patients could improve medication efficacy and decrease 
morbidity. It is possible that in obese asthmatics the 2 receptor may be more difficult to activate 
either due to receptor accessibility or substantial constraints in the signaling machinery at the 
receptor locus. Understanding why 2 agonists and ICS are less effective at controlling symptoms 
may allow for further pharmacologic refinements. The information from these studies will allow for 







 Obesity is associated with an increased prevalence and severity of asthma that coincides 
with racial disparities present in both conditions. The main rescue and controller medications have 
been shown to be less effective in obese asthmatics. Figure 1 below shows where the pathologies 
 
of obesity may dampen or disrupt the treatment pathways available for asthma. More research is 
needed to understand the mechanisms for the decreased efficacy of ICS and 2 agonists in obese 
asthmatic patients. This may allow for improved control of asthma in patients at an increased risk 
of poor health outcomes. 
 
Figure 1: Obesity related pathologic changes interfere with asthma control at many levels 
making control with standard therapies inadequate. The blue arrows show the direction in 
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